Pricing Log in Create free account

Citius Oncology, Inc. (CTOR) vs Sofgen Pharma S.A (PROCF)

Citius Oncology, Inc. and Sofgen Pharma S.A are both Drug Manufacturers Specialty & Generic companies. Sofgen Pharma S.A is the larger, with a market value of $114.0M against $69.4M — 1.6× the size. Citius Oncology, Inc. has negative trailing earnings, so its P/E is not meaningful; Sofgen Pharma S.A trades at 0.1×. Sofgen Pharma S.A has the higher net margin (9.52% vs 0.00%) and the higher return on invested capital (15.2% vs −67.2%). Across the 12 metrics below, Sofgen Pharma S.A leads on 9 and Citius Oncology, Inc. on 3.

Valuation

Metric CTOR PROCF Drug Manufacturers Specialty & Generic median
P/E n/m 0.07 19.25
P/S n/m 0.01 2.11
P/B 2.00 n/m 1.78
Price to free cash flow n/m 0.04 16.14
EV/EBITDA n/m 3.32 12.58
EV/Sales n/m 0.71 2.73
Earnings yield (62.67%) 1,354.00% (4.38%)
Free cash flow yield (39.72%) 2,469.89% 0.00%

Profitability

Metric CTOR PROCF Drug Manufacturers Specialty & Generic median
Gross margin — 56.16% 53.94%
Operating margin 0.00% 17.01% 0.00%
Net margin 0.00% 9.52% 0.00%
Free cash flow margin 0.00% 17.66% 0.00%
Return on equity (126.58%) (213.06%) (0.40%)
Return on assets (45.20%) 8.82% (3.32%)
Return on invested capital (67.15%) 15.21% 0.00%

Growth

Metric CTOR PROCF Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — 5.10% 10.01%
EPS growth (last fiscal year) (9.68%) (270.30%) 49.06%
Revenue growth, 5-year CAGR — (1.82%) 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CTOR PROCF Drug Manufacturers Specialty & Generic median
Debt to equity 0.50 (435.78) 0.05
Current ratio 0.73 0.64 2.31
Net debt to EBITDA (0.40) (7.21) 0.97

Dividend

Metric CTOR PROCF Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.57%
Payout ratio — — 0.27

Size

Metric CTOR PROCF Drug Manufacturers Specialty & Generic median
Market cap 69.36m 113.95m 276.90m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack